LRCX vs NKTR · P/E 71, rev $23.23B vs rev $21.0M
Lam Research Corp (LRCX) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
LRCX currently screens at market cap $467.94B and trailing P/E 70.9. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the LRCX and NKTR stock pages for the full models.
Not investment advice.